Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Adams Respiratory Therapeutics

This article was originally published in The Tan Sheet

Executive Summary

Adams has entered into a definitive agreement with Cardinal Health to repurchase the manufacturing assets and operations in Fort Worth, Tex., for $28 mil. and will take ownership of the facility July 31, the company announces July 27. Cardinal originally purchased the site - which houses manufacturing facilities for Mucinex and Humibid - from Adams in 2004, a decision that was "absolutely the right decision for our company at the time," according to Adams CEO Michael Valentino. Now two years later with marketing and advertising for the Mucinex line more fully developed, it is "imperative" for Adams to make manufacturing another one of its core competencies, Valentino says. With the purchase, Adams will take on 270 new Texas-based employees, as well as a one-time pre-tax charge of $8 mil.-$10 mil. in the first quarter of fiscal 2007, which ends Sept. 30. Adams will make a $24 mil. cash payment upon the July 31 closing date and make the remaining cash payments during fiscal year 2007...

You may also be interested in...

House Of Representatives Concerned Over Complex Generics

The Committee on Energy and Commerce of the US House of Representatives has requested a set of documents from the FDA in order to assess whether the agency is doing enough to address the challenge of approving complex generics within its existing authorities, or whether additional authority is needed.

Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In

As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.



Pipeline Watch: Phase III Readouts For Surufatinib, Tislelizumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.






Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts